EN
登录

Meta平台因使用Flo应用的健康数据进行定向广告而违反了加州隐私法

Meta Platforms Violated California Privacy Laws by Using Flo App Health Data for Targeted Ads

GeneOnline 等信源发布 2025-08-05 23:09

可切换为仅中文


by Mark Chiang

马克·蒋

Share To

分享到

Meta Platforms, the parent company of Facebook, has been found in violation of California’s privacy laws for its handling of sensitive health data collected through the Flo period-tracking app. The findings stem from an investigation into how Meta allegedly accessed and used personal health information shared by users of the app without proper consent..

Meta平台公司,即Facebook的母公司,因处理通过Flo经期追踪应用收集的敏感健康数据而被发现违反了加州的隐私法。这一发现源于对Meta涉嫌在未经适当同意的情况下访问和使用该应用用户分享的个人健康信息的调查。

The investigation revealed that Meta obtained data from Flo Health, a widely-used menstrual cycle tracking application, and utilized it for targeted advertising purposes. This practice reportedly occurred despite assurances to users that their health information would remain private. California authorities determined that this activity breached the state’s Consumer Privacy Act, which mandates transparency and user control over personal data.

调查发现,Meta从广受欢迎的月经周期追踪应用Flo Health获取数据,并将其用于定向广告。尽管向用户保证其健康信息将保持私密,但据报道该行为仍然发生。加州当局认定此举违反了州《消费者隐私法》,该法要求对个人数据的透明度和用户控制权。

The case highlights ongoing concerns about how tech companies handle sensitive health-related information in an era where digital tools increasingly intersect with healthcare services..

该案件突显了在数字工具与医疗服务日益交织的时代,科技公司如何处理敏感健康相关信息的持续担忧。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源:GO-AI-ne1

Date: August 5, 2025

日期:2025年8月5日

Related posts:

相关内容:

CDMO Pricing Analysis: High Capacity Utilization Linked to Lower Costs

CDMO定价分析:高产能利用率与低成本相关

EVERSANA Announces Pharmaceutical Sales District Manager Role Covering Texas and Florida Territories

EVERSANA宣布了覆盖德克萨斯州和佛罗里达州地区的制药销售区经理职位

Robert F. Kennedy Jr. Reveals Stem Cell Treatment at Antigua Clinic Outside U.S. Regulatory Oversight

罗伯特·F·肯尼迪 Jr. 透露在美监管范围外的安提瓜诊所接受干细胞治疗

Gilead Sciences Partners with Kymera Therapeutics in $750 Million Deal to Develop CDK2-Targeting Cancer Drug

吉利德科学与凯米拉治疗公司达成7.5亿美元协议,合作开发靶向CDK2的抗癌药物

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作:

[email protected]

[email protected]

Author

作者

Mark Chiang

蒋志光

Related Post

相关内容

News Flash

新闻快讯

Optichannel Strategies Boost ROI Across Pharmaceutical Product Lifecycle Through Coordinated Multi-Platform Engagement

通过协调多平台参与,光学策略提升制药产品生命周期的ROI

2025-08-05

2025年8月5日